parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in late spermatids	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 12053

LYPD6 in dopamine neurons, braak+0.20 (p 0.597) → +0.62 (p 0.073)receipt 12061
LYPD6 in astrocytes, braak+0.02 (p 0.964) → +0.53 (p 0.145)receipt 12060

receipt 12061: LYPD6 in dopamine neurons, braak

power: full sample +0.42 (p 0.084, n 18), 95% CI -0.06 to +0.74. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.48 (p 0.045, n 18). holds up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.38 (p 0.120, n 18). could be the mix.
skeptic: leave-one-out range +0.32 to +0.55, sign flips 0; without severely affected donors +0.42 (p 0.084, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LYPD6 in dopamine neurons.

case closed: nothing better to follow up.

receipt 12060: LYPD6 in astrocytes, braak

power: full sample +0.15 (p 0.555, n 18), 95% CI -0.34 to +0.58. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.15 (p 0.555, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.14 (p 0.567, n 18). could be the mix.
skeptic: leave-one-out range +0.02 to +0.26, sign flips 0; without severely affected donors +0.15 (p 0.555, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for LYPD6 in astrocytes.

case closed: nothing better to follow up.

loading the receipts